tiprankstipranks
Innovative Pharmaceutical Biotech Limited (HK:0399)
:0399
Hong Kong Market
0399
Innovative Pharmaceutical Biotech
RESEARCH TOOLSreports

Innovative Pharmaceutical Biotech (0399) Ratios

Compare
0 Followers

Innovative Pharmaceutical Biotech Ratios

HK:0399's free cash flow for Q2 2025 was HK$0.14. For the 2025 fiscal year, HK:0399's free cash flow was decreased by HK$ and operating cash flow was HK$-4.99. See a summary of the company’s cash flow.
Ratios
TTM
Mar 24Mar 23Mar 22Mar 21
Liquidity Ratios
Current Ratio
 0.02 <0.01 0.03 <0.01 0.19
Quick Ratio
 0.02 <0.01 0.03 <0.01 0.19
Cash Ratio
 0.02 <0.01 <0.01 <0.01 0.04
Solvency Ratio
 -0.47 -0.33 0.10 -0.20 0.30
Operating Cash Flow Ratio
 <0.01 -0.01 -0.02 -0.02 -0.12
Short-Term Operating Cash Flow Coverage
 <0.01 -0.01 -0.02 -0.02 -0.31
Net Current Asset Value
HK$ -1.17BHK$ -1.05BHK$ -1.05BHK$ -1.23BHK$ -980.78M
Leverage Ratios
Debt-to-Assets Ratio
 0.98 0.92 0.73 0.86 0.68
Debt-to-Equity Ratio
 -1.39 -1.47 -1.65 -1.50 -1.71
Debt-to-Capital Ratio
 3.56 3.11 2.54 3.01 2.40
Long-Term Debt-to-Capital Ratio
 -0.10 -0.15 11.11 -0.14 2.57
Financial Leverage Ratio
 -1.42 -1.59 -2.26 -1.74 -2.54
Debt Service Coverage Ratio
 -0.01 -0.26 0.57 -0.01 2.12
Interest Coverage Ratio
 -0.10 -0.05 -0.06 -0.09 -0.13
Debt to Market Cap
 3.85 3.34 3.18 3.91 4.30
Interest Debt Per Share
 0.69 0.73 0.80 0.97 0.77
Net Debt to EBITDA
 -68.19 -3.22 3.16 -63.20 4.10
Profitability Margins
Gross Profit Margin
14.46%8.99%12.74%10.63%9.46%
EBIT Margin
-977.56%-14837.25%4805.16%-256.37%2031.24%
EBITDA Margin
-692.99%-14837.25%4819.43%-233.08%2050.35%
Operating Profit Margin
-1049.78%-634.29%-203.76%-256.37%-218.51%
Pretax Profit Margin
-34859.61%-27276.23%1497.15%-3153.82%326.88%
Net Profit Margin
-24861.29%-16544.09%1568.38%-3042.70%2660.73%
Continuous Operations Profit Margin
-34859.61%-27276.23%1497.15%-3153.82%326.88%
Net Income Per EBT
71.32%60.65%104.76%96.48%813.97%
EBT Per EBIT
3320.66%4300.28%-734.76%1230.18%-149.60%
Return on Assets (ROA)
-50.76%-31.88%7.48%-17.75%21.26%
Return on Equity (ROE)
76.98%50.78%-16.91%30.90%-53.98%
Return on Capital Employed (ROCE)
-813.98%-11.73%-1.36%-8.73%-1.88%
Return on Invested Capital (ROIC)
-2.33%-1.29%-1.01%-1.56%-1.82%
Return on Tangible Assets
-1634.93%-3891.74%1055.24%-2269.94%1362.02%
Earnings Yield
-219.40%-115.01%32.56%-80.68%135.92%
Efficiency Ratios
Receivables Turnover
 0.62 0.58 1.29 1.26 1.17
Payables Turnover
 1.85 13.69 3.10 1.79 1.24
Inventory Turnover
 14.48 0.00 0.00 0.00 0.00
Fixed Asset Turnover
 0.21 0.00 0.00 8.58 3.95
Asset Turnover
 <0.01 <0.01 <0.01 <0.01 <0.01
Working Capital Turnover Ratio
 >-0.01 >-0.01 >-0.01 -0.01 -0.03
Cash Conversion Cycle
 416.68 598.43 165.72 86.37 16.36
Days of Sales Outstanding
 589.02 625.09 283.29 289.79 311.26
Days of Inventory Outstanding
 25.21 0.00 0.00 0.00 0.00
Days of Payables Outstanding
 197.55 26.66 117.56 203.41 294.90
Operating Cycle
 614.23 625.09 283.29 289.79 311.26
Cash Flow Ratios
Operating Cash Flow Per Share
 <0.01 >-0.01 >-0.01 -0.01 >-0.01
Free Cash Flow Per Share
 <0.01 >-0.01 >-0.01 -0.01 >-0.01
CapEx Per Share
 0.00 0.00 0.00 0.00 0.00
Free Cash Flow to Operating Cash Flow
 1.00 1.00 1.00 1.00 1.00
Dividend Paid and CapEx Coverage Ratio
 0.00 0.00 0.00 0.00 0.00
Capital Expenditure Coverage Ratio
 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Coverage Ratio
 <0.01 -0.01 >-0.01 -0.01 -0.01
Operating Cash Flow to Sales Ratio
 1.11 -5.05 -1.26 -2.18 -1.11
Free Cash Flow Yield
0.89%-3.51%-2.61%-5.79%-5.65%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
 -0.46 -0.87 3.07 -1.24 0.74
Price-to-Sales (P/S) Ratio
 124.71 143.85 48.18 37.72 19.58
Price-to-Book (P/B) Ratio
 -0.33 -0.44 -0.52 -0.38 -0.40
Price-to-Free Cash Flow (P/FCF) Ratio
 112.15 -28.50 -38.36 -17.26 -17.69
Price-to-Operating Cash Flow Ratio
 101.90 -28.50 -38.36 -17.26 -17.69
Price-to-Earnings Growth (PEG) Ratio
 <0.01 <0.01 -0.02 <0.01 >-0.01
Price-to-Fair Value
 -0.33 -0.44 -0.52 -0.38 -0.40
Enterprise Value Multiple
 -86.19 -4.19 4.16 -79.38 5.06
Enterprise Value
 1.35B 1.30B 1.32B 1.49B 1.16B
EV to EBITDA
 -86.19 -4.19 4.16 -79.38 5.06
EV to Sales
 597.27 621.98 200.67 185.01 103.72
EV to Free Cash Flow
 537.12 -123.22 -159.80 -84.69 -93.71
EV to Operating Cash Flow
 537.12 -123.22 -159.80 -84.69 -93.71
Tangible Book Value Per Share
 -0.59 -0.61 -0.69 -0.84 -0.67
Shareholders’ Equity Per Share
 -0.40 -0.39 -0.40 -0.54 -0.38
Tax and Other Ratios
Effective Tax Rate
 0.00 0.00 0.00 0.00 -7.14
Revenue Per Share
 <0.01 <0.01 <0.01 <0.01 <0.01
Net Income Per Share
 -0.29 -0.20 0.07 -0.17 0.20
Tax Burden
 0.71 0.61 1.05 0.96 8.14
Interest Burden
 35.66 1.84 0.31 12.30 0.16
Research & Development to Revenue
 2.40 1.00 0.22 0.59 0.74
SG&A to Revenue
 7.52 5.43 1.96 2.11 1.55
Stock-Based Compensation to Revenue
 0.00 0.00 0.00 0.00 0.00
Income Quality
 >-0.01 0.02 -0.08 0.07 -0.34
Currency in HKD